Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades
CNBC's Becky Quick reports on the latest news.
India Today on MSN16h
Vertex: New non-opioid painkiller Journavx approved by FDA
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...
FDA approves first new non-opioid pain pill in decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...
Zacks.com on MSN2d
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.
No Opioids, No Addiction: FDA Approves First New Type of Painkiller in Decades
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...